Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.
Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.
Serrano-Martín
Xenón
X
Laboratorio de Bioquímica y Biología Molecular de Parásitos, Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Apartado 47577, Caracas 1041A, Venezuela.
Payares
Gilberto
G
Mendoza-León
Alexis
A
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005905:Glyburide / Q000494:pharmacology*; D007894:Leishmania mexicana / Q000187:drug effects*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D026902:Potassium Channel Blockers / Q000494:pharmacology*
D000981:Antiprotozoal Agents; D026902:Potassium Channel Blockers; D000255:Adenosine Triphosphate; D005905:Glyburide